EP3248970A1 — Forms of umeclidinium bromide
Assigned to Zentiva KS · Expires 2017-11-29 · 8y expired
What this patent protects
Solid forms of umeclidinium bromide, in particular its non-solvated form 1, novel crystalline forms A and B and an amorphous form, their characterization with the use of analytic methods, methods of their preparation and their use for the preparation of highly pure umeclidinium b…
USPTO Abstract
Solid forms of umeclidinium bromide, in particular its non-solvated form 1, novel crystalline forms A and B and an amorphous form, their characterization with the use of analytic methods, methods of their preparation and their use for the preparation of highly pure umeclidinium bromide.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.